Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties
Affibody molecules are a recently developed class of targeting proteins based on a
nonimmunoglobulin scaffold. The small size (7 kDa) and subnanomolar affinity of Affibody …
nonimmunoglobulin scaffold. The small size (7 kDa) and subnanomolar affinity of Affibody …
Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine
S Ahlgren, H Wållberg, TA Tran… - Journal of Nuclear …, 2009 - Soc Nuclear Med
The detection of human epidermal growth factor receptor type 2 (HER2) expression in
malignant tumors provides important information influencing patient management …
malignant tumors provides important information influencing patient management …
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake
Purpose Affibody molecules are low molecular weight proteins (7 kDa), which can be
selected to bind to tumour-associated target proteins with subnanomolar affinity. Because of …
selected to bind to tumour-associated target proteins with subnanomolar affinity. Because of …
188Re-ZHER2: V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment
M Altai, H Wållberg, H Honarvar, J Strand… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable
tumor-targeting properties. Studies concerning the influence of chelators on biodistribution …
tumor-targeting properties. Studies concerning the influence of chelators on biodistribution …
In Vivo Evaluation of Cysteine-Based Chelators for Attachment of 99mTc to Tumor-Targeting Affibody Molecules
Affibody molecules present a new class of affinity proteins, which utilizes a scaffold based on
a 58-amino acid domain derived from protein A. The small (7 kDa) Affibody molecule can be …
a 58-amino acid domain derived from protein A. The small (7 kDa) Affibody molecule can be …
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule
Purpose Monitoring HER2 expression is crucial for selection of breast cancer patients
amenable to HER2-targeting therapy. The Affibody molecule Z HER2: 342 binds to HER2 …
amenable to HER2-targeting therapy. The Affibody molecule Z HER2: 342 binds to HER2 …
Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine
S Ahlgren, K Andersson, V Tolmachev - Nuclear medicine and biology, 2010 - Elsevier
INTRODUCTION: Molecular imaging of human epidermal growth factor receptor type 2
(HER2)-expression in malignant tumors provides potentially important information for patient …
(HER2)-expression in malignant tumors provides potentially important information for patient …
Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging
TA Tran, D Rosik, L Abrahmsén, M Sandström… - European journal of …, 2009 - Springer
Purpose The purpose of this study was to design and evaluate a novel platform for labelling
of Affibody molecules, enabling both recombinant and synthetic production and site-specific …
of Affibody molecules, enabling both recombinant and synthetic production and site-specific …
Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence
Purpose Expression of human epidermal growth factor receptor type 2 (HER2) in malignant
tumours possesses well-documented prognostic and predictive value. Non-invasive imaging …
tumours possesses well-documented prognostic and predictive value. Non-invasive imaging …
[HTML][HTML] Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
M Oroujeni, SS Rinne, A Vorobyeva… - International journal of …, 2021 - mdpi.com
Radionuclide imaging of HER2 expression in tumours may enable stratification of patients
with breast, ovarian, and gastroesophageal cancers for HER2-targeting therapies. A first …
with breast, ovarian, and gastroesophageal cancers for HER2-targeting therapies. A first …